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1. Introduction 
Pharmacogenetics and pharmacogenomics are gaining importance both in the clinical setting 
and in forensic pathology to investigate causes of death where no findings emerge from 
autopsy, and in the medical liability arena where scientific issues meet the justice system 
(Pilgrim et al., 2011). Generally speaking, Pharmacogenetics is the study of how genetic 
variations give rise to differences in drug response, while pharmacogenomics (PGx) is the 
application of genomic technologies to the discovery of new therapeutic targets (Evans & 
Relling, 1999). Nevertheless, there is a diversity of opinion regarding the definitions and 
benefits of pharmacogenetics and pharmacogenomics. Depending on the purpose, 
pharmacogenetics can be used to define applications of single gene sequences or a limited 
set of multiple gene sequences, but not gene expression or genome-wide scans, to study 
variations in DNA sequences related to drug action and disposition. Pharmacogenomics can 
be used to define applications of genome-wide single-nucleotide polymorphism (SNP) scans 
and genome-wide gene expression analyses to study variations influencing drug action 
(Lesko et al., 2003). Some authors use a very broad definition of pharmacogenomics 
including the study of inter-individual variations in whole-genome or candidate gene single 
nucleotide polymorphisms (SNP maps), haplotype markers and alterations in gene 
expression or inactivation that might be correlated with pharmacological function and 
therapeutic response. Pharmacogenetics is narrower in definition and refers to the study of 
inter-individual variations in DNA sequence related to drug absorption and disposition 
(pharmacokinetics) or drug action (pharmacodynamics), including polymorphic variation in 
genes encoding transporters, drug-metabolizing enzymes, receptors and other proteins 
(Lesko & Woodcock, 2004). With the accumulating knowledge of human genomic variation, 
the Human Genome Project offers the opportunity to develop personalized medicine, 
decreasing adverse drug reactions and increasing the efficacy of drug treatment 
(Weinshilboum & Wang, 2004). Historically, Johansson & Ingelman-Sundberg (Johansson & 
Ingelman-Sundberg, 2011) consider that inter-individual variation in response to a 
xenobiotic was probably described first by Pythagoras in 510 BC when he noted that some 
individuals developed hemolytic anemia after ingestion of fava beans. Then, they record 
that at the beginning of the last century, Garrod and Oxon suggested the involvement of a 
genetic component in biochemical processes where the cause of inter-individual differences 
in adverse reactions was because of enzyme deficiencies (Garrod, 1902, as cited in Johansson 
& Ingelman-Sundberg, 2011). Observations implying that genetic variation was responsible 
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for the diversity in some drug responses was established nearly 50 years ago, with the 
discovery that deficiency in glucose-6-phosphate dehydrogenase (G6DP) results in 
hemolytic anemia following ingestion of the anti-malarial primaquine (Beutler, 1959). 
Another example is succinylcholine, which is administered as an adjunct to anesthesia and 
can induce prolonged apnea due to altered kinetics of a pseudocholinesterase (Lehmann & 
Ryan, 1956). In 1959, Vogel coined the term of pharmacogenetics to describe inherited 
differences in drug response (Vogel, 1959). The best-known example of a genetic defect in 
drug biotransformation is the acetylation polymorphism in tuberculosis therapy with 
Isoniazid characterized by mutations in N-acetyltransferase-2 (NAT2) on chromosome 8 
(Evans et al., 1960). Alvan et al. (Alvan et al., 2001) remember the case of debrisoquine, an 
antihypertensive agent inducing orthostatic hypotension in a small percentage of 
individuals. The reason for the exaggerated effect was found to be the lack of an enzyme 
almost exclusively responsible for the metabolic elimination of debrisoquine and the 
affected subjects were classified as poor metabolizers of debrisoquine (Mahgoub, 1977, as 
cited in Alvan et al, 2001). The enzyme named “debrisoquine hydroxylase” is now known as 
CYP2D6. The oxidation of sparteine was found to be catalyzed by the same enzyme 
(Eichelbaum, 1975, 1979 as cited in Alvan et al, 2001). Now it is well-established that the 
therapeutic failure of drugs, and adverse side-effects in individuals may also have a genetic 
component due to genetic variations in the receptors, ion channels, transporter, enzymes 
and regulatory proteins involved in drug metabolism that may influence 
pharmacodynamics (e.g. the binding and functional capacity of the receptor or regulatory 
proteins) and pharmacokinetics, consisting in drug bio-availability at the level of metabolic 
enzymes and transporters. Most studies have focused on single nucleotide polymorphisms 
(SNPs) in genes encoding important metabolizing enzymes, like the cytochrome P450 
enzyme superfamily, revealing an association with clinical phenotypes of drug 
efficacy/toxicity (Bishop & Ellingrod, 2004; Korkina et al., 2009; Mellen & Herrington, 2005; 
Wilkinson, 2005; Yang et al., 2010). One of the goals of pharmacogenetics is to develop 
predictive genetic tests to reduce the risks associated with drug administration (de Leon et 
al., 2006, 2009). According to the World Health Organization (WHO), adverse drug reactions 
(ADRs) are any harmful, unintended reactions to medicines that occurs at doses normally 
prescribed for prophylaxis, diagnosis and therapy and in some cases can lead to death 
(Edwards & Aronson, 2000). ADRs represent a significant clinical and economic problem: a 
prospective study conducted in the United Kingdom showed that 6.5% of hospital 
admissions are related to ADRs (Pirmohamed et al., 2004). According to the Food and Drug 
Administration (FDA), the frequency of reported serious and fatal adverse drug events 
increased 2.6 fold from 1998 through 2005 (Moore et al., 2007). Moreover, it has been 
estimated that ADRs were between the fourth and sixth leading causes of death in the world 
due to treatment with drugs like anti-inflammatories, analgesics, antidepressants, sedatives, 
anticoagulants and antibiotics (Carleton et al., 2009; Lazarou et al., 1998). Given the 
association between response to treatment and genetic variability on the basis of clinical 
trials, the European Medicines Agency (EMEA) and the FDA currently recommend the use 
of biomarkers in informing prescribing decisions for certain drugs (Frueh et al., 2008). 
Moreover, growing information is available on biomarkers indicating whether a therapy 
could work on a particular individual. In 2004, a “Personalized Medicine Coalition” was 
launched in the USA, giving strong input to the US Senate bill on the Patient-Centered 
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Outcome Research Act. But questions arise, including: Will pharmacogenetics in general be 
accepted by physicians and patients? “Safe and effective medicines for all” is a vision that 
will not come true in general. Furthermore, even if its outcome and cost-effectiveness have 
to be proven, personalized medicine can currently contribute to solving the problems of lack 
of efficacy, drug resistance and adverse effects in some indications, and this opportunity 
should be used (Cascorbi, 2010). The scientific literature highlights the magnitude of this 
public health problem at different levels and point of views and illustrates the need for 
improved systems to select the appropriate drug dosage to achieve the optimal therapeutic 
response, avoid therapeutic failure and minimize side-effects and toxicity (Davies et al., 
2009). Recently, Sim et al. (2011) emphasize the need of updated databases for providing 
guidance to both scientists, physicians, regulatory agencies, and industries to cope with this 
major problem in human health. The medico-legal implications are evident both for medical 
liability issues and in forensic death investigation. 
2. Genetic polymorphism of Cytochrome P450 (P450 or CYP) 
The primary site of drug metabolism is the liver, where enzymes chemically change drug 
components into substances known as metabolites that are then bound to other substances 
for excretion mainly through the kidneys, lungs or bodily fluids or by intestinal re-
absorption. Some drugs do not change chemical structure and are removed from the body 
as such. Drug pharmacokinetics and pharmacodynamics are regulated by complex chemical 
reactions with the participation of numerous proteins encoded by different genes, deputies 
for the transport and metabolism of drugs, or involved in their mechanism of action 
(Weinshilboum, 2003). Two different types of metabolic reactions are involved: in phase 1 
molecules are characterized by oxidation, reduction and hydrolysis reactions, in phase 2 
drugs are conjugated with other compounds and then discarded (Johansson & Ingelman-
Sundberg, 2011; Zhou et al., 2008). If two or more polymorphic genes regulate drug 
metabolism and transport inside a cell, the variability in the response to treatment depends 
on the interaction of these gene variants. The cytochrome P450 enzyme system plays a 
central role in phase I oxidative metabolism of the vast majority of prescribed drugs and 
also of endogenous substances (Bertz & Granneman, 1997). The genes coding for these 
enzymes are called CYP. The Human Genome Project identified 57 human CYPs divided 
into families and subfamilies based on structural similarity in amino acid sequence of the 
enzymes. Enzymes in families 1 to 3 are involved in the detoxification of exogenous 
chemicals, whereas the remaining groups are mainly active in the metabolism of 
endogenous compound like steroids, fatty acids and bile acids (Ingelman-Sundberg & Sim, 
2010). Many of the genes involved in drug metabolism are highly polymorphic and all 
researchers specify the different CYP variants as reported at the Human CYP allele 
nomenclature web site www.cypallele.ki.se (Oscarson & Ingelman-Sundberg, 2002). Sim et 
al. (Sim et al, 2011) describe that the main purpose of the CYP-allele website is the 
management of new allele designations based on recognized nomenclature guidelines, 
facilitation of rapid publication, as well as providing a readily available summary of alleles 
and their associated effects. In addition they summarize the inclusion criteria of the new 
alleles in the website: submission of new alleles is achieved by contacting the Webmaster of 
the CYP-allele Website, whereby the data characterizing the allele is reviewed for potential 
allele name designation. All information is kept confidential and a manuscript in 
preparation can often serve as a good basis for review and discussion between the author 
and the Webmaster. Designation of allele names outside the CYP-allele nomenclature 
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committee is not advised, due to the apparent risk of confusion in the literature. 
Submissions with respect to additional functional in vivo and in vitro characterization of 
alleles listed are also highly relevant, and aids in keeping the CYP-allele Website up to date. 
2.1 P 450 genes family: From genotype to phenotype  
Of all the isoforms of the P450 gene family, CYP2D6, CYP2C19, CYP3As, CYP2C9, CYP2B6, 
CYP2C8, CYP2A6 and CYP1A2 are the most important and polymorphic enzymes and are 
responsible for several phase I metabolism xenobiotics (Anzenbacher & Anzenbacherová, 
2001; Daly, 2003; Ingelman-Sundberg, 2004). In particular, CYP2D6, characterized by a high 
inter-individual variability in catalytic activity mainly caused by genetic polymorphisms, 
will be described in depth. The genetic bases of the polymorphism are single nucleotide 
polymorphisms, insertions/deletions and gene copy number variations (Ingelman-
Sundberg et al., 1999). Because of such variability, individuals could be classified into four 
different phenotypes: ultra-rapid metabolizers (UM) with more than two active gene copies 
on the same allele or increased expression of a single gene, extensive metabolizers (EM) 
carrying two functional alleles, intermediate metabolizers (IM) with one defective allele or 
two partially defective alleles, and poor metabolizers (PM) lacking functional enzymes due 
to defective or deleted genes. PM and UM are the most clinically important phenotypes: PM 
individuals are at risk of having a higher than expected serum concentration in relation to 
the drug dose and hence more side-effects, especially in the case of drugs with a narrow 
therapeutic index (White, 2010; Prandota, 2010). Instead, UMs may require higher doses and 
more frequent administration of a drug in an active form to achieve optimal therapeutic 
concentrations. However, when an inactive “pro-drug” must be converted to the active 
metabolite (e.g. codeine and tamoxifen), the therapy will be ineffective in PM subjects and 
UMs will metabolize it quickly with accumulation of the metabolite and consequent toxicity. 
As a result, drug toxicity is related to metabolizer status (Ingelman-Sundberg et al., 1999; 
van der Weide & Steijns, 1999). Moreover, the phenomenon of phenocopying must be taken 
into account where EM individuals turn into apparent PM or IM phenotypes because of 
drug-drug interactions (Owen et al., 2009). Many drugs also inhibit or induce the activity of 
CYPs and knowledge of CYP–drug relations is therefore essential to recognize incompatible 
drug combinations and allows individualized therapies (Mishra et al., 2010). For this 
purpose, a user-friendly platform for researchers and health professionals was developed 
where each drug was attributed to those CYPs involved in drug metabolism as substrate, 
inhibitor or inducer. The SuperCYP database contains 1170 drugs with more than 3800 
interactions including references (Preissner et al., 2010). Nevertheless, epigenetics, defined 
as heritable phenotypic changes not involving alteration in nuclear DNA, promises answer 
to interindividual variability in drug response not associated to genetic polymorphism 
(Ingelman-Sundberg & Gomez, 2010). Indeed, the CYPs expression can be influenced by 
diet, lifestyle and environmental pollutants. Update of P450 epigenetics knowledge and its 
relevance for cancer risk and treatment is reported in a recent review: CYP1A1, CYP1A2, 
CYP1B1, CYP2E1, CYP2W1, CYP2A13 have been shown to have epigenetics component in 
their expression regulation (Rodriguez-Antona et al., 2010).  
2.2 CYP2D6  
CYP2D6 is the most extensively studied drug metabolizing enzyme in humans and its 
polymorphism was the first among polymorphic P450s to be characterized at the molecular 
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level. About 20-25% of clinically used drugs are metabolized by this enzyme including beta-
blockers, antiarrhythmics, antidepressants, neuroleptics, analgesics and anti-cancer drugs. 
Most of them are metabolized to the inactive form; others like codeine, tramadol and 
tamoxifen are bio-activated. CYP2D6 is the only drug metabolizing CYP which is not 
inducible and therefore genetic variation plays a major role in the inter-individual variation 
in enzyme activity (Ingelman-Sundberg et al., 2007). The gene, located near two cytochrome 
P450 pseudogenes on chromosome 22q13.1, is highly polymorphic and more than 80 allelic 
variants related to the gene activity have been described (Zhou, 2009). The wild type allele is 
CYP2D6*1 and major variants associated with decreased and abolished enzyme catalytic 
activity are CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*17 and CYP2D6*41. 
Multiple active gene copies are responsible for ultra-rapid metabolizer individuals. CYP2D6 
phenotypying is characterized in vivo by the ratio of urinary amounts of parent compound 
relative to oxidative metabolite. The most commonly used probe substrates have been 
debrisoquine, sparteine and dextromethorphan. On the basis of the urinary metabolic ratio 
(MR), PM, UM, EM and IM phenotypes have been classified, but CYP2D6 genotyping to 
predict metabolic status is considered a valid alternative to traditional phenotyping 
methods because genetic characteristics remain unchanged throughout life and are not 
influenced by environmental and physiologic factors (Gaedigk et al., 2003; Zanger et al., 
2004). One of the most commonly used methods for CYP2D6 genotyping consists in a 
combination of a first long-PCR (polymerase chain reaction) step designed to amplify the 
entire CYP2D6 gene in a single fragment of about 5 kb followed by minisequencing, a 
multiplex PCR by SNP genotyping method (Fig. 1), screening the 11 most important 
polymorphic positions of the gene (Sistonen et al., 2005). The inferring phenotype from 
CYP2D6 genotype information is based on different approaches including the conventional 
classification in PM, IM, EM and UM, established on the assumption of dominance, in which 
the phenotype is determined by the most efficient allele (Sistonen et al., 2007). However, this 
method does not consider inter-individual variability in urinary metabolic ratio-based 
phenotypes of subjects with identical genotype and the complexity of allele combinations. 
For this reason, the “activity score” (AS) system has been evaluated to translate genotype 
into a qualitative measure of phenotype and to overcome the difficulties of interpretation 
and comparison of different studies on CYP2D6 activity. For each variant allele a value is 
assigned based on CYP2D6 activity: “1” to the fully functional alleles and “0” to non-
functional alleles, “0.5” or “0.75” to reduced activity alleles and double the value to 
duplicated genes. The AS is the sum of the individual allele values (Gaedigk et al., 2008). 
2.2.1 Distribution of CYP2D6 polymorphism 
Inter-ethnic differences in the distribution of CYP2D6 genotypes have been described 
(Bernard et al., 2006; Gaedigk et al., 1999, 2002; Gaedigk & Coetsee, 2008; Griese et al., 2001; 
Kitada, 2003; Leathart et al., 1998; Luo et al., 2004; Wan et al., 2001; Zhou et al., 2009). In a 
worldwide survey (Sistonen et al., 2007) 5-10% of Europeans are PMs with the highest 
frequency of CYP2D6*4 variant, while the UMs are most represented in North Africa and 
Oceania (40% and 26% respectively) due to the high percentage of gene duplication. In 
Asian populations alleles with absent CYP2D6 activity are very rare, but the *10 allele, 
causing a decreased enzyme function, occurs quite frequently leading to a high percentage 
of IMs. The *1 and *2 variants are the most represented in all population groups and their  
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Fig. 1. Electropherograms of the multiplex PCR by SNP genotyping method 
(minisequencing) of two different individuals. Peaks correspond to 11 polymorphic 
positions (100C>T, 1023C>T, 1661G>C, 1707delT, 1846G>A, 2549delA, 2613-15delAGA, 
2850C>T, 4180G>C, 2988G>A, 3183G>A) of the CYP2D6 gene. a) Electropherogram of a 
homozygous CYP2D6*1/*1 wild type genotype and b) Electropherogram of a homozygous 
CYP2D6*4/*4 genotype 
homogeneous geographic distribution could be regarded as the result of a long-term 
selective pressure maintaining the high frequency of alleles coding for a full-function 
enzyme. However, few rarely region-specific alleles associated with an altered enzymatic 
activity are observed and seem to be geographically dispersed over all four continents 
(Gaedigk et al., 2006, 2007, 2009, 2010; Luo et al., 2005). Ethnic specificity has become an 
integral part of pharmacogenetics research but caution is required against the use of 
continental labels to lump together heterogeneous populations. The Asian category, for 
example, is applied to individuals of distinct ethnicity and/or living in different countries or 
regions of the vast continent of Asia. Not surprisingly, significant variation in the 
distribution of pharmacogenetics polymorphism is detected among Asians (Suarez-Kurtz, 
2008). Nevertheless, with increasing global migration, admixture gains relevance as an 
CYP2D6 *1/*1 
CYP2D6 *4/*4 
a)
   b)
www.intechopen.com
 
Forensic Pharmacogenetics 
 
273 
additional challenge to the successful worldwide implementation of pharmacogenetics in 
clinical practice. The Brazilian population, with tri-hybrid ancestral roots in Amerindian, 
European and African groups and five centuries of extensive inter-ethnic mating, provides a 
valuable model for studying the impact of admixture on the conceptual development and 
clinical implementation of pharmacogenetics-informed prescription. Recognition of this fact 
is important in the design and interpretation of pharmacogenetics clinical trials in 
Brazilians, but does not imply that pharmacogenetics-informed drug prescription requires 
investigation of individual ancestry. Rather, individual genotyping should be directed to 
polymorphisms of proven clinical utility, irrespective of biogeographical ancestry (Suarez-
Kurtz, 2010). 
2.3 CYP2C9  
CYP2C9 accounts for approximately 20% of total hepatic CYP content and metabolizes 
approximately 15% of clinically used drugs including S-warfarin, tolbutamide, phenytoin, 
losartan, diclofenac and celecoxib (Goldstein, 2001). To date, at least 33 variants of CYP2C9 
(*1B through to *34) have been identified (Yasar et al., 1999, 2002). CYP2C9*2 and CYP2C9*3 
differ from the wild-type CYP2C9*1 by a single point mutation: CYP2C9*2 is characterised 
by a 430C>T exchange in exon 3 resulting in an Arg144Cys amino acid substitution, whereas 
CYP2C9*3 shows an exchange of 1075A>C in exon 7 causing an Ile359Leu substitution in the 
catalytic site of the enzyme (Wang et al., 2009). The CYP2C9 polymorphism is clinically 
highly significant and also substrate-dependent (Rosemary & Adithan, 2007; Xie et al., 2001). 
Marked inter-racial differences have been reported: CYP2C9*2 and CYP2C9*3 were both 
found with highest frequencies in Northern African and European populations. The 
frequency of CYP2C9*2 decreases rapidly when moving from Europe toward the east, and it 
is practically zero in Eastern Asian populations. CYP2C9*3 occurs more evenly in different 
geographic regions. (Sistonen, et al., 2009). The polymorphism in admixed populations was 
studied in the context of warfarin dose requirements. Variant alleles CYP2C9*5, CYP2C9*6, 
CYP2C9*8 and CYP2C9*11 occur in Africans but are rare or absent in Europeans. 
Genotyping of the six polymorphisms could be justified in Brazilians and, most likely 
African-Americans, but not Europeans, in whom only CYP2C9*2, CYP2C9*3 might be 
adequate for predicting the CYP2C9 polymorphism (Suarez-Kurtz, 2010). Candidate-gene 
association studies for warfarin response have identified CYP2C9 and VKORC1, which 
codes for warfarin's target, vitamin K epoxide reductase, responsible for most of the genetic 
effect. VKORC1 is a key enzyme of the vitamin K cycle and molecular target of coumarin 
anticoagulants. Among whites and Asians, VKORC1 polymorphisms have shown a 
consistently significant influence on warfarin response, accounting for 11% to 32% of dose 
variability. Among North American blacks, VKORC1 polymorphisms account for 4% to 10% 
of the variability in dose. Given that genetic diversity is known to be greater in persons of 
African descent, investigators have hypothesized that other VKORC1 polymorphisms, or 
combinations of multiple polymorphisms (haplotypes), may better explain the variation in 
dose in this group (Limdi et al., 2010).  
2.4 CYP2C19 
The metabolism of tricyclic antidepressants, benzodiazepines and proton pump inhibitors is 
catalyzed mainly by CYP2C19. The most common genetic variation, designated CYP2C19*2 
(c.G681A), leads to a splicing defect that functionally affects the enzyme. Other alterations 
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have also been reported such as loss-of-function: CYP2C19*3 (c.G636A; stop codon), 
CYP2C19*4 (c.A1G; transition in the initiation codon), and CYP2C19*5 (c.C1297T; amino acid 
substitution) (Santos et al., 2011). A variant defining an ultra-rapid metabolizer has been 
identified (Sim et al., 2006). Pronounced ethnic differences exist in the frequencies of the 
non-functional alleles: a low frequency of up to 5% in the Caucasian and African 
populations, higher in Oriental populations (23%). CYP2C19*2 and CYP2C19*3 are together 
responsible for the majority of PM alleles, of which CYP2C19*3 is mainly found in Asians 
(Chen et al., 2008; Xie et al., 2001). 
2.5 CYP1A2 and CYP2A6 
CYP2A6 is an inducible enzyme primarily expressed in the liver and was first recognized for 
its involvement in the metabolism of coumarin. The CYP2A6 gene locus spans a region of 
6kbp and has been physically mapped to the long arm of chromosome 19. Thirteen allelic 
variants have been discovered due to point mutation, deletion, and gene conversion, and 
several of these result in altered enzyme activity. CYP2A6 is involved in the metabolism of 
nicotine, some procarcinogens and several toxins. Variants may affect smoking, cancer and 
the treatment of cigarette smoking. (Xu et al., 2002). CYP1A2 metabolizes clozapine, tacrine, 
tizanidine and theophylline, a number of procarcinogens like benzo[a]pyrene and aromatic 
amines, and several important endogenous compounds (e.g., steroids). CYP1A2 is subject to 
reversible and/or irreversible inhibition by a number of drugs, natural substances and other 
compounds. The CYP1A gene cluster has been mapped on chromosome 15q24.1, with a 
close link between CYP1A1 and 1A2 sharing a common 5‘-flanking region. More than 15 
variant alleles and a series of subvariants of the CYP1A2 gene have been identified and 
some of them have been associated with altered drug clearance and response and disease 
susceptibility (Zhou et al., 2010). 
2.6 CYP2B6 and CYP2C8  
CYP2B6, mapped to the CYP2 gene cluster on chromosome 19, plays a major role in the 
biotransformation of several therapeutically important drugs including cyclophosphamide, 
ifosfamide, tamoxifen, ketamine, artemisinin, nevirapine, efavirenz, bupropion, sibutramine 
and propofol. This enzyme also metabolizes arachidonic acid, lauric acid, 17-estradiol, 
estrone, ethinylestradiol and testosterone (Mo et al., 2009). Genetic polymorphisms in 
CYP2B6 are defined in terms of 29 allelic variants many of which are associated with 
increased, decreased or abolished enzyme activity (Watanabe et al., 2010). Overall, there is a 
marked inter-individual variability in CYP2B6 activity, but current pharmacogenetic 
knowledge is not sufficient to provide efficient tools to predict the specific capacity for 
metabolism of CYP2B6 substrates (Ingelman-Sundberg et al., 2007). CYP2C8 is a 
polymorphic phase I drug-metabolizing enzyme involved in the metabolism of several 
therapeutic drugs including paclitaxel, amodiaquine, troglitazone, amiodarone and 
verapamil, and has also been implicated in the activation of procarcinogenic compounds 
(Totah & Rettie, 2005). The gene is located on chromosome 10q24 in a cluster with CYP2C19 
and CYP2C18 and 14 different allelic variants have been reported (http://www. 
cypalleles.ki.se/cyp2c8.htm). The main CYP2C8 polymorphisms code for the amino acid 
changes I269F, R139K, K399R and I264M. These single nucleotide polymorphisms define 
three main non-wild-type alleles, CYP2C8*2 (I269F), CYP2C8*3 (R139K and K399R) and 
CYP2C8*4 (I264M). The CYP2C8*2 allele has been found in black populations with an allele 
frequency of 18% but is very rare in white subjects (Dorado et al., 2008). 
www.intechopen.com
 
Forensic Pharmacogenetics 
 
275 
2.7 CYP3A 
The CYP3A drug-metabolizing enzymes facilitate the metabolism and elimination of a wide 
range of structurally different xenobiotics and of 50% of all clinically used therapeutic 
drugs. In addition, they participate in the metabolism of key endogenous substrates, such as 
retinoic acid, steroid hormones and bile acids (Domanski et al., 2001; Ingelman-Sundberg et 
al., 2007; Thummel & Wilkinson, 1998). The four CYP3A genes lie within a 218 kb region of 
chromosome 7q22.1 in the following order: CYP3A5, CYP3A7, CYP3A4, and CYP3A43 
(Lamba et al., 2002; Westlind et al., 2001). More than 30 SNPs have been identified in the 
CYP3A4 gene (Du et al., 2006; Garsa et al., 2005). Generally speaking, variants in the coding 
regions of CYP3A4 occur at allele frequencies <5% and appear heterozygous with the wild-
type allele. These coding variants may contribute, but are unlikely to be the major cause of 
inter-individual differences in CYP3A-dependent clearance, because of the low allele 
frequencies and limited alterations in enzyme expression or catalytic function (Eiselt et al., 
2001). The most common variant, CYP3A4*1B, is an A-392G transition in the 5'-flanking 
region with an allele frequency ranging from 0% in Chinese and Japanese to 45% in African-
Americans. Studies have not linked CYP3A4*1B with alterations in CYP3A substrate 
metabolism (Garcia-Martin et al., 2002; Lamba et al., 2002). CYP3A5 is polymorphically 
expressed in adults with readily detectable expression in about 10–20% in Caucasians, 33% 
in Japanese and 55% in African-Americans. The primary causal mutation for its 
polymorphic expression (CYP3A5*3) confers low CYP3A5 protein expression and its allele 
frequency varies from approximately 50% in African-Americans to 90% in Caucasians 
(Adler et al., 2009; Lamba et al., 2002). CYP3A7 is considered to be the major fetal liver 
CYP3A enzyme. Three of the mutations represent SNPs (CYP3A7*1B, *1D and *1E) and 
occurs in regions outside those associated with the regulation of CYP3A transcription. The 
fourth mutation (CYP3A7*1C) consists of the replacement of 60 bp from the CYP3A4 gene 
with the corresponding sequence from the CYP3A7 gene (Lamba et al., 2002). 
3. Personalized therapy: ethical and legal issues 
Current prescribing practice involves administration of a standard “one size fits all” starting 
dose and is often a process of trial and error, varying the prescription until the most suitable 
treatment is found (Sadee, 1998). However, such a procedure exposes the patient to possible 
side-effects. In fact, around 21% of all outpatients suffer some kind of adverse reaction to 
drugs prescribed by their physician (Queneau et al., 2007). By investigating drug 
metabolism related to individual genetic polymorphism, pharmacogenetics has a significant 
impact on the clinical setting so that forensic implications may arise throughout the public 
health sector. The concept of “therapy with the right drug at the right dose in the right 
patient” was highlighted just about ten years ago (Mancinelli et al., 2000) and 
pharmacogenetic tests are now available for a number of drugs by biotechnology 
companies, some with FDA approval, as reported in Wong et al., (2010): Luminex xTag® 
(Luminex Corporation, TK, USA), Roche AmpliChip® (Roche, Basel, Switzerland), 
Affymetrix DMET® chip (Affymetrix, CA, USA), Autogenomics INFINITI™ Analyzer 
(Autogenomics, CA, USA), Osmetech eSensors® (WA, USA), ParagonDx (NC, USA), and 
ABI PRISM® SNaPshot™ (Applied Biosystems, CA, USA) and TaqMan® assays (Applied 
Biosystems). In addition, the Authors underlined the limitations: existing evidence to 
demonstrate significant and medically relevant correlations for many disease-causing genes 
and variants, limited detection of genetic variants within the context of each testing 
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platform, clinical interpretation of genotype results including environmental factors, and 
transplanted organs interfering with testing. Nevertheless, SNP arrays covering 5 million 
SNPs will soon become a reality and the cost for whole-genome sequencing is rapidly 
decreasing (Sim & Ingelman-Sundberg, 2011). The influence of genetic polymorphism on 
drug failure or toxicity can be illustrated by some significant examples.  
3.1 Moving to clinical practice: significant examples 
An increasing number of studies on psychiatric patients have shown that genetic variation 
of CYP2D6 and CYP2C19 affects the metabolism of antidepressants and antipsychotics, 
thereby explaining the different therapeutic effects in different patients (Kirchheiner & 
Seeringer, 2007). Of the patients treated with antidepressants 10-20% react adversely and 25-
35% do not respond to the medication. This can lead to treatment for patients being selected 
in what has been described as a “trial and error” fashion, as physicians try different 
pharmacological agents with their patients in order to select the best treatment (Morley & 
Hall, 2004). Given their selective mechanism of action, selective serotonin reuptake 
inhibitors (SSRIs) replaced tryciclic antidepressants and monoamino oxidase inhibitors, but 
because of their inhibitory effects on various CYP enzymes, SSRIs may be associated with 
clinically relevant pharmacokinetic interactions with other medications (Spina et al., 2008). 
In dementia, approximately 10-15% of direct costs are attributed to pharmacological 
treatment and only 10-20% of the patients are moderate responders to conventional anti-
dementia drugs, with questionable cost-effectiveness (Cacabelos, 2008). Pharmacogenetic 
and pharmacogenomic factors are reported to be responsible for 75-85% of the therapeutic 
response in Alzheimer’s disease (AD) patients treated with conventional drugs. 
Cholinesterase inhibitors of current use in AD, such as donepezil, tacrine and galantamine, 
are metabolized via CYP-related enzymes. EMs and IMs are the best responders, and PMs 
and UMs are the worst responders to pharmacologic treatments in AD. At this early stage of 
the development of pharmacogenomic/pharmacogenetic procedures in AD therapeutics, it 
seems very plausible that the pharmacogenetic response in Alzheimer's disease depends on 
the interaction of genes involved in drug metabolism and genes associated with Alzheimer's 
disease pathogenesis (Cacabelos, 2007). Paracetamol and tramadol were the most popular 
analgesics among individuals taking warfarin. A recent study supports clinical evidence of 
the significance of the adverse warfarin-paracetamol interaction, although the mechanism 
responsible for the interaction is not clear. Some case reports of warfarin tramadol 
interactions have been published and a CYP2D6-related mechanism has been proposed 
(Launiainen et al., 2010). Warfarin (4-hydroxy coumarin), the most frequently prescribed 
oral anticoagulant, has a narrow therapeutic index and a wide inter-individual variability in 
dose requirement: an increase or decrease in anticoagulant activity are associated with the 
risk of hemorrhagic or thrombotic events (Kamali & Wynne, 2010). Variants in the 
cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKOR) genes have been 
shown to have a significant effect on warfarin dose requirement. Warfarin 
pharmacogenetics has become a case study for personalized medicine. Algorithms 
incorporating selected SNPs in two genes, CYP2C9 and VKORC1, show improved dose 
prediction compared with algorithms based solely on clinical and demographic factors. 
However, the performance of these algorithms differs among racial groups, with a higher 
proportion of variability in dose explained in whites than in Asians or blacks. The first 
comprehensive assessment of the influence of six common VKORC1 SNPS and haplotypes 
on warfarin dose among Asians, blacks and whites with the use of the largest racially 
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diverse cohort captured the influence of common genetic variation in VKORC1 on 
variability in warfarin dose by a single polymorphism (either -1639G>A or 1173C>T) across 
all racial groups. Incorporation of additional VKORC1 SNPs or haplotypes did not improve 
dose prediction. Therefore, current evidence supports the use of -1639G>A (or 1173C>T) to 
capture dose variability related to VKORC1. Both VKORC1 and CYP2C9 influenced warfarin 
dose among individual patients in all three racial groups studied (Limdi et al., 2010). The 
case of tamoxifen is well-documented in the management of women with hormone receptor 
(HR) positive breast cancer (Hoskins et al., 2009). Tamoxifen is a pro-drug that is 
metabolized to its main active metabolite endoxifen by the cytochrome P450 2D6. Null or 
reduced enzyme activity in women treated with tamoxifen results in worse outcomes in 
terms of cancer relapse and lower event-free survival rates compared to extensive 
metabolizers. Addition data are required for a mandatory use of a CYP2D6 genetic test, 
considering the demonstrated potential effect of CYP2C19 polymorphism on relapse risk 
during tamoxifen treatment (Sim & Ingelman-Sundberg, 2011). In addition, selective 
serotonin reuptake inhibitor antidepressant drugs such as paroxetine and fluoxetine have 
also been used to manage tamoxifen-induced hot flushes. These drugs potently inhibit the 
metabolism of tamoxifen by CYP2D6 and thus potentially may lessen the efficacy of 
tamoxifen (Singh et al., 2011). Recently, it has been pointed out that there is sufficient reason 
to be aware of the real possibility of herbal products inhibiting cytochrome P450 enzymes. 
Considering that self-administration of complementary products is an increasingly common 
trend worldwide, the interactions may significantly increase the risk of ADR (Sevior et al., 
2010). The picture that emerges highlights the crucial role of the physician to understand 
when to order the pharmacogenetics test and how to use the results in clinical decision-
making (Robertson et al., 2002). The authors emphasized that if the risk of side-effects from 
a drug is great, a physician who failed to order the test indicative of toxicity could be found 
to have been negligent and future lawsuits for failure to give a test or properly interpret it 
will ensue, both reflecting and reinforcing acceptance of pharmacogenetic testing as an 
ordinary part of medical practice. 
3.2 Legal and ethical issues 
The development of pharmacogenetics has important implications in the medico-legal and 
forensic field because the classic topics of informed consent, shared genetic information, 
privacy and data base collection arise (Vaszar et al., 2002). Nevertheless the problem of 
orphan patients, non-responders for all available drug options, might have unforeseen 
consequences to avoid the label “hard to treat” (Robertson, 2001). Some patients might not 
want to be tested for pharmacogenetics profiles and this leads to the question of what a 
physician should do if a patient refuses to be genotyped. The responsibility of health care 
professionals will need to be defined as to who (doctors, pharmacist, clinical chemists) is 
responsible for the application of new technologies (genotyping) and what kind of patient 
counseling is needed (van Delden et al., 2004). A recent paper (Hamburg & Collins, 2010) 
highlighted that today about 10% of labels for FDA-approved drugs contain 
pharmacogenomic information — a substantial increase since the 1990s. Furthermore, there 
has been an explosion in the number of validated markers but relatively little independent 
analysis of the validity of the tests used to identify them in biologic specimens. The National 
Institute of Health (NIH) and the FDA will invest in advancing translational and regulatory 
science, and will better define regulatory pathways for coordinated approval of co-
developed diagnostics and therapeutics, develop risk-based approaches for appropriate 
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review of diagnostics to assess their validity and clinical utility more accurately, and make 
information on tests readily available. As the field advances, they expect to see more 
efficient clinical trials based on a more thorough understanding of the genetic basis of 
disease. The impact on the medico-legal field is evident. But, there are two schools of 
thought on how tort liability may affect personalized medicine, i.e., whether fear of lawsuits 
will tend to accelerate progress or slow it down. Tort suits include product liability suits 
against manufacturers and negligence suits against physicians and other providers of 
health-related services (Evans, 2007). Recently, Wong et al. (2010) stressed that personalized 
medicine by means of pharmacogenomics may have a dramatic impact on the justice system 
in ways we are only beginning to understand. They stated that if personalized medicine has 
already entered the curricula of well-regarded medical schools such as that of Johns 
Hopkins University (MD, USA), law schools offer no analogue. For example, “The FDA 
relabelled some drugs such as warfarin with CYP2C9 and vitamin K epoxide reductase 
complex 1 to reduce bleeding. If pharmacogenetics retrospectively reveals that the warfarin 
patient was at high risk and testing was not initially performed, litigation may follow. 
Indeed, some lawyers advertise on the Internet for cases involving warfarin-related errors. 
Consequently, pharmacogenomics may become part of defensive medicine”. An important 
issue for legal and ethical use of pharmacogenetic tests arises from the evidence of genetic 
polymorphism distribution in different ethnic groups. CYP2D6 gene polymorphism shows 
that the distribution of PMs, IMs and UMs varies in different ethnic groups so inter-ethnic 
differences in drug response highlight the need to evaluate the genetic makeup of 
individuals before prescribing drugs, also considering that the recent demographic 
movements and back migration of populations are reshaping the picture of genetic diversity 
within the native population (Suarez-Kurtz, 2010). A recent review by McNamara 
(McNamara, 2008) discusses investigations of pharmacogenomics in heart failure and the 
challenge of converting genomic heterogeneity into a usable clinical tool, concluding that 
investigators are beginning to delineate the genomic basis for differences in drug efficacy 
between black and white heart failure cohorts. The influence of CYP2C9 and VKORC1 
genotypes on warfarin dose requirements has been demonstrated in diverse racial and 
ethnic patient groups and to choose a warfarin starting dose, dosing algorithms have been 
developed that incorporate clinical, demographic and genetic information. Because of these 
significant issues, the Journal of Health & Life Sciences Law explored personalized or 
patient-tailored medicine addressing the relevance of genetic information, and how race and 
genetics have affected and may impact on the development of medicines, 
pharmacogenomics and personalized medicine in the United States (Braff et al., 2008). A 
second part discussed current and proposed federal and state laws and regulations intended 
to protect individuals from the misuse of genetic information, including uses that 
discriminate based on genetic predispositions (Braff et al., 2009). It was recently pointed out 
(Nebert et al., 2008) that numerous reasons exist to show that an "unequivocal genotype" or 
even an "unequivocal phenotype" is virtually impossible to achieve in current limited-size 
studies of human populations. The problem of insufficiently stringent criteria leads to a 
decrease in statistical power and consequently an equivocal interpretation of most 
genotype-phenotype association studies. It remains unclear whether personalized medicine 
or individualized drug therapy will ever be achievable by DNA testing alone. The authors 
ask “Where are we, today, in our understanding of the role of human genetics and genomics 
in drug toxicity, efficacy and therapeutic failure? Few high-prevalence predominantly 
monogenic genes that do make a difference in metabolism of various drug substrates (e.g., 
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CYP2D6, NAT2, TPMT, CYP2C19) might contribute perhaps 15% to 20% to the (EM or PM) 
phenotype, whereas a contribution of 90% or more is expected for the gene responsible for a 
monogenic human disease. If we know that dozens or hundreds of additional downstream 
genes might affect the ultimate outcome of a particular drug, how can we integrate and 
assemble this knowledge into a diagram or equation?” A recent paper discussed the 
possible application of genotyping for depression, cardiovascular diseases and 
thromboembolic disorders, gastric ulcer, malignant diseases and tuberculosis (Tomalik-
Scharte et al., 2008). The authors noted that thousands of manuscripts addressing 
pharmacogenetic questions in in vitro studies and clinical trials have been published, but it 
seems that the way to a broader use of pharmacogenetics approaches at the patients’ 
bedside is quite laborious. The unknown exact relationship between the genotype and 
phenotype, although in many cases the genotype explains most of the inter-individual 
variability, the lack of prospective clinical studies in large patient cohorts and no reliable 
data on the cost effectiveness of screening procedures explain the slow progress in clinical 
pharmacogenetics/pharmacogenomics. In this respect, Zhou (Zhou, 2009) wrote that the 
functional impact of most CYP2D6 alleles has not been systematically assessed for most 
clinically important drugs that are mainly metabolized by CYP2D6, though some initial 
evidence has been identified for a very limited number of drugs. The majority of reported in 
vivo pharmacogenetic data on CYP2D6 are from single-dose and steady-state 
pharmacokinetic studies of a small number of drugs. Pharmacodynamic data on CYP2D6 
polymorphisms are scanty for most drug studies. Given that genotype testing for CYP2D6 is 
not routinely performed in clinical practice and there is uncertainty regarding genotype-
phenotype, gene-concentration and gene-dose relationships, further prospective studies on 
the clinical impact of CYP2D6-dependent metabolism of drugs are warranted in large 
cohorts. The expectation is that this research field will provide both the industry and 
clinicians with useful pharmacogenomic biomarkers that can aid in procedures for drug 
development and specific drug treatment in order to optimize the results and improve 
human health. The process is slow, and for a solid basis for decisions on mandatory 
biomarkers to be used further large prospective clinical studies are required. One fruitful 
manner in which this can be achieved is a closer collaboration between industry and 
academics (Johansson & Ingelman-Sundberg, 2011).  
4. Forensic investigation  
In the forensic context, pharmacogenetics can assist in the interpretation of drug-related 
deaths, especially accidental drug poisonings or cases of sudden death with “nearly normal 
autopsy "(Karch, 2007), called “white autopsy” in Italy. The author claims that the ability to 
identify "invisible diseases" with post-mortem genetic testing has become a reality far more 
quickly than anyone had ever imagined and this development is not without irony: “at the 
same time that many clinicians are expressing frustration about the lack of tangible gains 
provided by the Human Genome Project and pathologists are wondering about the viability 
of their field, DNA technology is about to reshape the field of forensic pathology”. The role 
of pharmacogenetic analysis in forensic investigation has already been emphasized as the 
holistic approach of molecular analysis connected to macroscopic, microscopic and 
toxicological observations, constituting an integral part of modern medico-legal study of 
death (Koski et al., 2007). Nevertheless, the area of medico-legal investigation also involves 
occupational medicine due to the consequences on toxic-exposed workers. In this field the 
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role of CYP2D6 genotype in determining parkinsonism resulting from pesticide exposure 
may play an important role (Elbaz et al., 2004). Pesticide exposure significantly increases the 
risk for Parkinson’s disease even when the poor metabolizer allele is in the heterozygote 
state. Interestingly, poor metabolizers are less common in the Parkinson’s disease group in 
rarely exposed subjects (Deng et al., 2004). Pharmacogenetics also plays an important role in 
drug-addiction studies: methadone is metabolized through the liver by cytochrome P450 
enzymes CYP3A4, CYP2D6 and CYP1A2 and buprenorphine is mainly metabolized by 
CYP3A4 enzyme. A recent review reported that Caucasians who lack CYP2D6 function 
appear to be protected from oral opioid dependence since this genotype is under-
represented in the opiate-addicted population and these poor metabolizers are satisfied with 
the withdrawal and anticraving relief provided by methadone treatment. Ultra-rapid 
metabolizer heroin-dependent patients have felt dissatisfied with methadone therapy and 
can do well using buprenorphine because it is not significantly metabolized by CYP2D6 
(Haile et al., 2008). In a limited number of cases of methadone toxicity, Wong et al. (2003) 
showed that the prevalence of poor metabolizers was higher but not significantly different 
from that of a control group (n=23). They concluded that CYP2D6 mutations may not yet be 
directly associated with methadone toxicity, and pharmacogenomics, complementing other 
case findings in molecular autopsy, is considered an adjunct in interpreting the methadone 
toxicity of poor and intermediate metabolizers. 
4.1 Post mortem analysis 
Genetic variation and its effects on metabolism can be applied to post-mortem analysis to 
help resolve cases initially believed to be suicide or classified as sudden unexplained deaths 
especially in cases where poisoning, incapacitation, inebriation or certain diseases where 
pharmacotherapy is an essential treatment (such as epilepsy, depression, cardiac diseases or 
diabetes) are factors in the cause of death. An additional benefit is that pharmacogenetics 
analysis may provide health information (certainly only via proper ethical disclosure 
practices) to at-risk relatives (Budowle & van Daal, 2009). As reported recently, the medico-
legal community has yet to fully exploit genetic variation as a parameter in determining the 
causes of death as done by the National Academy of Science in recognizing the 
underutilization of molecular autopsies (Sajantila et al., 2010). The authors of this valuable 
review stressed that an individual’s pathophysiological phenotype affecting drug efficacy 
depends on genetic constitution and several other factors such as developmental stage, 
physiological and environmental factors, association with disease or specific conditions. 
Hence, some of these studies may be ethically unacceptable or practically impossible to 
perform in the clinical setting, but may be more readily performed post-mortem as part of 
the cause of death investigation or retrospectively with proper authorization. Therefore they 
recommend that serious consideration and support be given to studies of medico-legal 
genetics not just because of the impact on death investigation but because of the tremendous 
value such information can have for personalized medicine. From this point of view and 
due to the increasing attention paid to sudden cardiac death, the role of pharmacogenetics is 
now studied in more depth considering that cytochrome P450 enzymes in acquired Q-T 
prolongation are more prevalent than the congenital form. Several risk factors have been 
identified with use of Q-T prolonging drugs as the most frequent cause (van Noord et al., 
2010). The CYP2D6 hydroxylation capacity has already been implicated in causing 
elongation of the Q-T interval: patients treated with thioridazine that inhibits CYP2D6 
activity itself, may be prone to an increased risk of death due to sudden arrhythmia such as 
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“torsades de pointes” (Llerena et al., 2002). In general, fatal drug toxicity has been associated 
with either slow or ultra-rapid CYP2D6 metabolism depending on the substrate activation 
or inactivation. Sallee et al., (2000) described the clinical course of a nine-year-old boy 
diagnosed with attention-deficit hyperactivity disorder, obsessive-compulsive disorder and 
Tourette's disorder and treated with a combination of methylphenidate, clonidine and 
fluoxetine. After experiencing signs and symptoms suggestive of metabolic toxicity marked 
by bouts of gastrointestinal distress, low-grade fever, incoordination and disorientation for 
more than ten months, the patient presented generalized seizures, lapsed into status 
epilepticus followed by cardiac arrest and subsequently expired. At autopsy, blood, brain 
and other tissue concentrations of fluoxetine and norfluoxetine were several-fold higher 
than expected based on literature reports for overdose situations. The medical examiner's 
report indicated death caused by fluoxetine toxicity. As the child's adoptive parents 
controlled medication access, they were investigated by social welfare agencies. Further 
genetic testing of autopsy tissue revealed a gene defect at the cytochrome P450 CYP2D6 
locus, resulting in poor metabolism of fluoxetine. As a result of this and other evidence, the 
investigation of the adoptive parents was terminated. One of the first demonstrations that 
genetic variation in drug metabolizing enzyme can be analyzed in post-mortem blood was 
performed studying the CYP2D6 gene variations correlated to the tramadol metabolite ratio 
in blood in 33 Finnish autopsy cases where tramadol was found (Levo et al., 2003). A series 
of fatal poisonings due to amitriptyline (AT) abuse not all due to suicides was reported in 
Finland in 2005 (Prahlow & Landrum, 2005). In view of this, Koski et al. (2006) investigated 
the genetic variation at CYP2D6 and CYP2C19 genes with the metabolic ratio of the drug in 
post-mortem samples. No cases of fatal poisoning due to a combination of AT treatment and 
poor metabolizer phenotypes was found, with the exception of one case of female suicide 
with a very high concentration of AT and homozygous null alleles at CYP2D6. The authors 
emphasized the role of confounding factors in the interpretation of pharmacogenetics 
results such as age and enzyme inhibition by drugs. The pharmacogenetics analysis in a 
post-mortem forensic setting to reveal the cause and manner of death demonstrated doxepin 
poisoning associated with a completely non functional CYP2D6 genotype, considering that 
CYP2D6 is a major factor involved in the large inter-individual variation in doxepin 
metabolism (Koski et al., 2007). However, ultrarapid metabolizer for duplication in CYP2D6 
may also be responsible for fatal toxicities. The risk of opioid poisoning to breast-fed 
neonates whose mothers had been prescribed codeine was studied after a fatal case. 
Neonatal morphine plasma concentrations were simulated for various combinations of 
CYP2D6 genotype and morphine clearance. Neonates of mothers with the ultrarapid 
CYP2D6 genotype and neonates of mothers who are extensive metabolizers have 
comparable risks of opioid poisoning (Willmann et al., 2009). A tragic case was reported in 
2006 when a 13-day-old baby died from morphine poisoning. Review of the medical records 
revealed that the mother had been prescribed Tylenol® 3 (codeine 30 mg and acetaminophen 
500 mg) in the immediate post-partum period. Initially she took two tablets twice daily, but 
she halved the dose on post-partum day two owing to somnolence and constipation. 
Following the development of poor neonatal feeding, the mother expressed milk and stored 
it in a freezer. Analysis of the milk for morphine using a specific enzyme-linked 
immunosorbent assay method for morphine revealed a concentration of 87 ng/mL. The 
mother was later classified as a UM of CYP2D6 substrates, carrying one extra copy of a 
functional CYP2D6 gene (Madadi et al., 2007). Since 2007, the FDA has required the 
manufacturers of prescription codeine products to include information on the label to 
inform prescribing doctors about these risks and to help prevent morphine overdose in 
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breast-fed infants. Recently, the death of a ten-month-old boy found dead in the bed after 
exposure to-ethylmorphine was reported. The morphine-to ethylmorphine ratio in blood 
from the deceased was higher than expected for the exclusive ingestion of ethylmorphine. 
The explanations considered that the metabolism of ethylmorphine involves both the de-
ethylation to morphine by CYP2D6 and the conjugation to glucuronide by the 
glucuronosyltransferase UGT2B7. The activity of the enzymes varies for genetic reasons and 
is influenced by age. Infants have lower glucuronidation capabilities than adults and 
CYP2D6 activity may exceed adult levels in infancy. The CYP2D6 genotyping excluded the 
hypothesis of an ultra-rapid phenotype (Helland et al., 2010). Nevertheless, the genetic 
variability of CYP2D6 and possibly in UGT2B7 was studied in a large number of women 
receiving codeine for obstetric pain while breast-feeding. Breast-fed infants of mother who 
were CYP2D6 UM combined with UGT2B7 *2/*2 are at increased risk of potentially life-
threatening central nervous system depression (Madadi et al., 2009). Molecular autopsy 
research was also performed on fentanyl that is clinically used as an adjunct to surgical 
anaesthesia or for chronic pain management and its toxicity may be partially due to CYP 
3A4*1B and 3A5*3 variant alleles, resulting in variable fentanyl metabolism. The study of 25 
fentanyl-related deaths by the analysis of fentanyl and norfentanyl in post-mortem blood 
samples showed the first scientific evidence of CYP3A5 involvement in fentanyl metabolism: 
homozygous CYP3A5*3 causes impaired metabolism of fentanyl, and CYP3A4*1B and 3A5*3 
variants may help to certify the fentanyl toxicity (Jin et al., 2005). Furthermore, 
pharmacogenetic analysis has gained burgeoning interest in suicidal cases both for the 
correlation with antidepressant therapy and in researching endogenous serotonin 
metabolism. A study of the genetic profile of individuals in relation to the presence of 
CYP2D6 and CYP2C19 genes in 242 fatal intoxications, 262 suicides and 212 natural deaths 
showed that those dying from suicide (including hanging, shooting, sticking/cutting or 
jumping from a height) included a higher number carrying more than two active CYP2D6 
genes. A possible explanation was the lower concentration level of prescribed medication in 
these ultra-rapid metabolizers resulting in ineffective treatment, but no information was 
available on the medical history of the suicide cases (Zackrisson et al., 2010). Discussing the 
results of Isacsson et al. (Isacsson et al., 2009) and the treatment of depression with 
antidepressants, mainly SSRI, in preventing suicide, Bertilsson (2010) recently reported that 
the data seem to indicate that serotonergic mechanisms are involved in the etiology of 
suicidal behaviour. An alternative explanation to the overrepresentation of CYP2D6 gene 
duplication among suicide cases was based on the presence of the CYP2D6 enzyme in the 
human brain where its distribution follows that of dopamine nerve terminals, 
demonstrating several endogenous substrates of CYP2D6 among which of special interest is 
the O-demethylation of 5-methoxytryptamine to serotonin. The author reported that 
serotonin might then be synthesized in dopaminergic neurons by CYP2D6 and act as a false 
transmitter in wrong (inhibitory?) neurons.  
5. Conclusion 
Current pharmacogenetics research in the clinical and medico-legal settings provides new 
options for disease treatment and prevention of ADR avoiding correlated death, and for 
screening interactions with the polymorphic P450 enzymes early on in drug development. 
The ensuing information will be translated into routine clinical practice in the years to come 
benefitting millions of patients worldwide (Ingelman-Sundberg & Sim, 2010). In the future, 
the research in relatively new fields such as epigenetics and small nuclear RNA mediated 
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mechanisms will increase the number of useful biomarkers for personalized therapy. 
Indeed, epigenetics providing answers to interindividual variability in drug response not 
associated to genetic polymorphism, could represent the bridge that connects the 
environment to the genome (Gomez & Ingelman-Sundberg, 2009). In this respect, the area of 
pharmacoepigenomics has a promising future (Ingelman-Sundberg & Gomez, 2010). In 
medico-legal setting, molecular autopsy is becoming a reality also considering that robust 
techniques suitable for implementation in forensic laboratories are broadening the genetic 
analysis of P450 gene polymorphism. But we agree with Sajantila et al. (2010) that “in some 
ways this situation now confronting medico-legal geneticists is similar to the early years of 
the DNA level human identification era. The societal and judicial systems sought the 
technology and scientists had serious challenges to cope with demands. Like DNA-based 
identification at that time, fundamental pharmacogenetic research needs to be performed so 
that our knowledge is sufficient to render valid and reliable interpretations related to 
medico-legal genetic findings”. Significantly, Wong et al. (2010) state that personalized 
justice complements personalized medicine, but “personalized justice” in a firm foundation 
should be based on sound legal principles as well as reliable and valid evidence-based 
studies, not on ‘junk’ science and unsubstantiated case reports. Furthermore, the American 
Academy of Forensic Sciences supports the National Academy of Science’s 13 
recommendations (National Academy of Sciences, 2009, as cited in Wong et al., 2010) and 
the following principles: the need for strong scientific foundations; laboratory accreditation; 
certification of technicians; the standardization of terminology; ethical protocols; 
governmental oversight; and the education of legal professionals, including judges, in 
forensic scientific methods and principles. 
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